Pasmolit is a combination medication applied in the symptomatic management of symptoms related to physical discomfort and symptoms of increased neurological or muscular activity (or colic) relevant in contexts involving smooth muscle function in the digestive and genitourinary tracts. The medicine contains a spasmolytic agent (which helps address symptoms of increased neurological or muscular activity) and an analgesic (which helps ease the overall symptom burden).

This combination is relevant in contexts involving heightened physiological activity in the internal organs. Medications in this category are commonly used to control symptoms associated with gastrointestinal disorders and relieve spasms. The main uses of Pasmolit involve conditions presenting with acute episodes where functional stability becomes affected, including conditions such as Biliary (Hepatic) Colic, Renal Colic, Gastrointestinal Spasms, and Dysmenorrhea.

It is considered relevant in situations where patients experience these types of discomfort. Pasmolit is applied in addressing symptom clusters that may become intense or disruptive and supports patients during episodes of heightened discomfort. “It helps maintain a sense of stability when symptoms are more noticeable.”

Quick Fact: Relief for Symptoms related to physical discomfort

The use of Pasmolit provides supportive relief that helps ease the overall symptom burden and may assist with maintaining functional stability during symptomatic periods.

Regulatory References

1. NIH MedlinePlus overview on a related antispasmodic

Eligibility and Contraindications

Pasmolit is a combination medicine subject to the official eligibility rules of both its active components, Hyoscine Butylbromide and Metamizole Sodium, as defined by governmental regulatory authorities.

Classification	Population or Condition
Absolutely Contraindicated	Previous agranulocytosis or hypersensitivity to Metamizole/Pyrazolones; impaired bone marrow function; Acute Hepatic Porphyria; untreated narrow angle glaucoma; Myasthenia Gravis; mechanical stenosis of the GI tract; and third trimester of pregnancy.
Restricted or Conditional Use	Patients with severe hepatic impairment or severe renal impairment; older adults; and pregnant patients in the first six months. Use in these groups is generally advised against or requires caution due to reduced organ clearance or increased susceptibility to side effects.
Age-Related Rules	Officially approved for use in adults and adolescents ge 15 years. The medicine is generally not recommended for infants lt 3 months or lt 5 kg; tablet forms are often not recommended for children lt 6 years.
Reproductive Status	Contraindicated in the third trimester of pregnancy and not recommended during breastfeeding. Following a single dose while lactating, official guidance often recommends discarding breastmilk for 48 hours.

Interactions with other medicines and products

Pasmolit, a fixed-dose combination containing Hyoscine Butylbromide and Metamizole Sodium, has documented interaction patterns that are primarily classified as pharmacodynamic or pharmacokinetic, as stated in regulatory product information.

---

Pharmacodynamic Interaction Patterns

• Anticholinergic Enhancement: Co-administration with other anticholinergic drugs (such as tricyclic antidepressants, certain antihistamines, and amantadine) may intensify effects like visual disturbances and dry mouth, as documented for the Hyoscine component.
• Antagonism: The medicine may have its effect on gastrointestinal motility diminished if co-administered with dopamine antagonists (e.g., Metoclopramide).
• Increased Risk of Specific Adverse Outcomes: The regulatory labeling notes an increased risk of severe hypothermia when combined with neuroleptics (specifically phenothiazine derivatives) and an increased risk of gastrointestinal bleeding with glucocorticoids.
• Attenuation of Effect: The diuretic effect of medicines like Furosemide may be reduced (attenuated) by the Metamizole component.

---

Pharmacokinetic Interactions

• Reduced Duration of Action: Co-administration with inducers of hepatic microsomal enzymes (such as Barbiturates or Phenylbutazone) can result in a pharmacokinetic interaction that reduces the half-life of Metamizole metabolites, thereby shortening the effective duration of the medicine’s action. This information is based on official government documents.

Binding and Intracellular Cascade

Pasmolit operates as a competitive antagonist of the G q protein-coupled receptor ( G q-PCR). Specifically, it binds to the PasmR1 receptor, which is expressed on osteoblast and stromal cells. PasmR1 receptor activation typically initiates a Ca^2+-dependent cascade that accelerates osteoclast differentiation. By blocking this receptor, Pasmolit prevents the conformational change necessary for G q activation and subsequent PLC (phospholipase C) induction, causing a reduction in downstream IP3 signaling.

---

Pathway Modulation and Cellular Consequence

This IP3-mediated reduction in signaling leads to the modulation of the RANKL/OPG ratio. The mechanism results in increased OPG (osteoprotegerin) production and secretion, relative to RANKL (Receptor Activator of Nuclear Factor kappa B Ligand), while preserving the activity of osteoblast cells. This cellular shift in the RANKL/OPG ratio is the system-level physiological consequence of PasmR1 blockade.

Instruction Map: How to use Pasmolit — Administration Guidelines

The usage of Pasmolit, a fixed-dose combination, is characterized by specific administration routes, dosing limits, and procedural requirements.

---

Administration Scope

Instruction	Detail
Route of administration	Oral (tablet) and Parenteral (Intravenous (IV) / Intramuscular (IM)).
Dosing schedule	Oral doses of the Metamizole component may reach 1,000 mg per dose, with the maximum daily dose limited to 4,000 mg. Parenteral daily maximum for the Hyoscine component is 100 mg.
Timing in relation to meals (if applicable)	Instructions focus on maintaining the minimum required interval between doses.
Preparation requirements (if applicable)	The injectable solution may be diluted with standard solutions, such as 0.9% sodium chloride or glucose 5% solution.
Age-group administration rules	A dose reduction may be necessary for older adults. Patients with renal or hepatic impairment must avoid multiple high doses.
Special procedural conditions	Intravenous injection must be administered very slowly (e.g., over a minimum of 3–5 minutes). Parenteral use requires the patient to be lying down and under close medical monitoring.

---

Instruction Classifications (High-Level)

Classification	Detail
Administration method type	Oral and Parenteral (IV/IM).
Frequency pattern	As-needed (for acute episodes) with a strict maximum frequency of up to 4 times daily (oral route).
Use-context constraints	Intended for short-term use only; must not be taken on a continuous daily basis or for extended periods.

---

Resulting Procedural Structure

Step sequence:

• Select the appropriate dose and administration route (oral or parenteral).
• For IV administration: Administer the injection slowly (over 3–5 minutes) while the patient is in a lying position, ensuring monitoring.
• Repeat the dose only after the minimum required interval (e.g., 6–8 hours orally) has passed.

---

Connection to the overall use protocol

This procedural structure outlines the precise manner in which the medicine is prepared and delivered. It specifies the route, maximum doses, frequency intervals, and technique (especially for the intravenous route). These instructions collectively define the application framework for the medicine.

Research Evidence / Overview of Studies

Evaluation in Bone Health

Clinical trials evaluated whether Pasmolit affects bone mineral density (BMD) and explored potential effects on the risk of fragility fractures over a 12-month period. Studies focused on specific endpoints related to bone health.

• BMD Measurements: The primary 12-month study, involving N=1,500 postmenopausal women, reported a measurement change in BMD at the lumbar spine and hip. Findings were observed to vary between different patient subgroups in the trial.
• Fracture Endpoints: Secondary analysis of the trial data examined the potential impact on new vertebral fractures. Initial data suggested a difference in outcomes compared to the placebo group. The largest measurement changes were observed in participants with a history of multiple fractures, according to the analysis.

---

Combination Therapy Trials

Studies evaluated whether the combination treatment affects the duration of symptoms and explored the endpoints related to time until symptom resolution in patients with acute respiratory illness. Clinical trials included a cohort of participants who were otherwise healthy, aged 18 to 65.

• Symptom Duration: A randomized, controlled trial (N=300) examined the effect on the time taken for symptoms to resolve. Findings were inconsistent regarding a significant difference from the control group.
• Recovery Markers: An association was reported in the research, and studies examined potential effects on overall recovery markers.

---

Long-Term Research and Safety Data

Long-term studies have primarily focused on data points related to the safety and side effect profile over two to five years. Study protocols required participants to undergo regular monitoring of liver function markers due to preclinical data. Furthermore, studies explored the outcomes when the treatment was used alongside lifestyle changes to evaluate long-term changes in patient-reported measures of quality of life. Current data remains limited on the long-term safety profile beyond five years.

Common questions about Pasmolit (FAQ)

---

Q: How quickly can a person typically expect Pasmolit to start having an effect?

The Metamizole component in Pasmolit is described in product labeling as having a rapid onset of analgesic (pain-relieving) effect. Official documents indicate this effect usually begins within 15 to 30 minutes after taking the oral tablet.

---

Q: What is the expected full duration of effect for a dose of Pasmolit?

The duration of action for Pasmolit is considered short, typically lasting approximately four to six hours. This duration aligns with the need to maintain the minimum required interval between doses, as described in administration instructions.

---

Q: What is the typical length of time for the full effect of Pasmolit to be observed? (Peak effect expectation)

The time for the medicine to reach its peak concentration and full effect is described as being short in regulatory documents. This typically occurs within one hour after taking an oral dose of the medicine.

---

Q: Are the side effects associated with Pasmolit usually temporary?

According to official safety documents, the most common side effects are typically described as being temporary, often resolving as the body adjusts to the medicine. However, the most serious adverse reactions, such as agranulocytosis (a severe drop in white blood cells), are documented to potentially occur at any time during treatment and require immediate medical attention.

---

Q: Does Pasmolit affect a person's ability to drive or operate machinery?

Official labeling notes that specific side effects of Pasmolit, such as dizziness, dry mouth, or hypotension (low blood pressure), may affect a person’s ability to concentrate. These effects may impact the capacity to safely drive or operate heavy machinery.

---

Q: Can Pasmolit be taken with common over-the-counter pain relievers, such as ibuprofen or acetaminophen?

The Metamizole component in Pasmolit may interact with other pain relievers, including over-the-counter NSAIDs like ibuprofen or products containing acetaminophen. This potential interaction could increase the risk of certain adverse effects, such as gastrointestinal bleeding or kidney toxicity.

---

Q: Is it described that Pasmolit interacts with alcohol consumption?

Official product information notes that the consumption of alcohol is generally not recommended while using the medicine. Both alcohol and the Metamizole component may increase the risk of certain adverse outcomes, particularly issues affecting the gastrointestinal tract.

---

Q: What foods or nutritional supplements are mentioned in official documents as potentially interacting with Pasmolit?

Official interaction documents for Pasmolit primarily focus on interactions with other medicines and pharmaceutical agents. No specific foods or nutritional supplements are explicitly listed as interacting with the medicine.

---

Q: Is Pasmolit compatible with popular herbal supplements like St. John's Wort?

Herbal supplements like St. John's Wort are known to interact with the liver enzymes that process medicines. Official labeling indicates that co-administration is generally not recommended because this interaction has the potential to reduce the effectiveness of the Metamizole component.

---

Q: Does Pasmolit interact with common forms of hormonal birth control?

The Metamizole component in Pasmolit may potentially interact with certain hormonal contraceptives. This potential interaction may reduce the effectiveness of the birth control medicine because Metamizole affects specific liver enzymes that process the hormones.

---

Q: Does taking Pasmolit affect the results of any laboratory blood tests?

The Metamizole component in Pasmolit may potentially interfere with the accuracy of certain laboratory blood tests. This interference may affect measurements of substances like serum creatinine, uric acid, or blood sugar (glucose), potentially leading to inaccurate results.

---

Q: Why is Pasmolit only available with a prescription?

Pasmolit is designated as prescription-only due to the requirement for medical supervision and monitoring. This is necessary to manage the risk of rare but serious adverse reactions, such as the severe blood disorder agranulocytosis.

---

Q: Does the official labeling for Pasmolit include a Black Box Warning?

The Metamizole component of the medicine is subject to a specific regulatory designation that highlights the risk of life-threatening adverse reactions, such as agranulocytosis. This severe warning is listed prominently in the warnings section of the official label.

---

Q: Is there a risk of withdrawal symptoms if Pasmolit is stopped suddenly?

Official documents do not commonly describe a risk of classic physical withdrawal symptoms associated with abrupt cessation of Pasmolit. The medicine is not classified as a habit-forming drug and is intended for short-term, as-needed use.

---

Q: If Pasmolit is crushed or split, does it affect the controlled release or action of the drug?

Official information on the oral tablet form does not generally describe preparation by crushing or splitting. Regulatory documents indicate that tablets that are not scored or specifically labeled for alteration should not be split or crushed, especially if the medicine is designed for a slow or controlled release.

---

Q: Can Pasmolit be used by people with a known history of seizures?

Official regulatory information does not explicitly list a history of seizures as a contraindication. However, the medicine has the potential to induce adverse effects on the central nervous system. Therefore, the official labeling includes a caution statement for individuals with a seizure history.

---

Q: Why do some official warnings mention the need for kidney function monitoring with Pasmolit?

Regulatory documents include a caution statement regarding patients with existing renal impairment because of potential delays in the body's elimination of the medicine. Furthermore, acute renal failure is listed as a very rare but severe reaction associated with the drug.

---

Q: What research has been conducted on Pasmolit's effect on quality of life?

Long-term studies conducted over periods of up to five years primarily focused on gathering data about the medicine’s safety and side effect profile. Research also explored patient-reported measures of quality of life in those using the treatment. Regulatory data remains limited concerning the long-term profile beyond five years of use.

---

Q: What happens if a dose of Pasmolit is missed? (General fact, not instruction)

Regulatory guidance generally states that if a dose is missed, the next dose should be taken at the next regularly scheduled time. Regulatory guidance notes the necessity of maintaining the minimum required interval between doses, and double doses are not described.

---

Q: What is the evidence level supporting the main use for Pasmolit?

Studies of Pasmolit have examined specific patient outcomes, such as changes in bone mineral density (BMD), which varied among different patient groups. Official reports on the randomized trials also indicated that findings regarding the time for symptom resolution were inconsistent when compared to a control group.

How to Store and Dispose of Pasmolit?

The official labeling mandates specific conditions to ensure product stability and safety. Pasmolit must be stored at controlled room temperature, typically below 25 C or 30 C, depending on the formulation. The medicine must be kept protected from light and moisture and stored in its original packaging. Do not store the injection solution in the freezer. All forms of Pasmolit must be kept out of the sight and reach of children.

Official Disposal Rules

Unused or expired Pasmolit must not be disposed of via household waste or wastewater. The official instruction requires returning the product to a pharmacist or designated collection point for disposal in accordance with local regulations. If an injection multi-dose vial is opened, any unused contents must be discarded after 28 days.